Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Studies have shown that non-cancer patients taking opioid pain medication for a long period
of time can have decreased libido and decreased sexual function.
Individuals may be asked to take part in this study even if they have not taken opioid pain
medications in the last twelve months. These individuals would also be enrolled to learn if
long-term treatment of cancer-related pain with opioid medications results in decreased sex
hormones, decreased sex drive, and increased fatigue or depression.
Participants in this study will be asked to complete a set of questions about their sexual
functions, physical symptoms, and psychological symptoms such as fatigue and depression. It
will take about 25 minutes to complete the questionnaires.
Participants will have blood drawn (about 2 teaspoons of blood) to test their sex hormone
level. Participants who are identified as having low sex hormone level (hypogonadism) will
be referred to an endocrinologist for standard hormone replacement therapy.
This is a one-time evaluation, no follow-up visit or questionnaires are required.
This is an investigational study. A total of 108 individuals will take part in this study.
All will be enrolled at UTMDACC.
Observational Model: Case Control, Time Perspective: Prospective
Prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes
Arun Rajagopal, MD
M.D. Anderson Cancer Center
United States: Institutional Review Board
|U.T.M.D. Anderson Cancer Center||Houston, Texas 77030|